Quality of Care Indicators for Head and Neck Cancers: The Experience of the European Project RARECAREnet

Annalisa Trama, Laura Botta, Roberto Foschi, Otto Visser, Josep Maria Borras, Tina Žagar, Maja Primic-Žakelj, Francesca Bella, Nadya Dimitrova, Gemma Gatta, Lisa Licitra, Annalisa Trama, Laura Botta, Roberto Foschi, Otto Visser, Josep Maria Borras, Tina Žagar, Maja Primic-Žakelj, Francesca Bella, Nadya Dimitrova, Gemma Gatta, Lisa Licitra

Abstract

Background: Monitoring and improving quality of cancer care has become pivotal today. This is especially relevant for head and neck cancers since the disease is complex, it needs multi therapy, patients tend to be older, they tend to have comorbidities and limited social support. However, information on quality of care for head and neck cancers is scarce. In the context of the project "Information Network on Rare Cancers" we aimed to identify indicators of quality of care specific for the head and neck cancers management and to measure the quality of care for head and neck cancers in different EU Member States. Methods: We defined indicators of quality of care for head and neck cancers based on a multidisciplinary and expert-based consensus process at a European level. To test the proposed indicators, we performed an observational population-based retrospective study in four countries (Ireland, Italy, Netherlands, and Slovenia) in the years 2009-2011. Results: The main quality indicators identified are: availability of formalized multidisciplinary team, participation in clinical and translational research; timeliness of care, high quality of surgery and radiotherapy, and of pathological reporting. For head and neck cancers, the quality of care did not reach the optimal standards in most of the countries analyzed. A high proportion of patients was diagnosed at an advanced disease stage, showed delays in starting treatment (especially for radiotherapy), and there was only a very limited use of multi therapy. Conclusions: According to the achieved consensus, indicators of quality of care for head and neck cancers have to cover the patient journey (i.e., diagnosis and treatment). Our results, showed suboptimal quality of care across countries and call for solutions for ensuring good quality of care for head and neck cancer patients in all EU countries. One possible option might be to refer head and neck cancer patients to specialized centers or to networks including specialized centers.

Keywords: head and neck cancers; integrated care; population based studies; quality indicators; quality of care.

References

    1. van Overveld LF, Braspenning JC, Hermens RP. Quality indicators of integrated care for patients with head and neck cancer. Clin Otolaryngol. (2017) 42:322–9. 10.1111/coa.12724
    1. Licitra L, Keilholz U, Tahara M, Lin JC, Chomette P, Ceruse P, et al. . Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer. Oral Oncol. (2016) 59:73–9. 10.1016/j.oraloncology.2016.06.002
    1. Institute of Medicine Crossing the Quality Chasm: A New Health System for the Twenty-first Century. Washington, DC: National Academy Press; (2001).
    1. Albert JM, Das P. Quality indicators in radiation oncology. Int J Radiat Oncol Biol Phys. (2013) 85:904–11. 10.1016/j.ijrobp.2012.08.038
    1. McDowell L, Corry J. Radiation therapy quality assurance in head and neck radiotherapy–moving forward. Oral Oncol. (2019) 88:180–5. 10.1016/j.oraloncology.2018.11.014
    1. Andry G, Hamoir M, Leemans CR. Quality assurance in head and neck surgery: special considerations to catch up. Eur Arch Otorhinolaryngol. (2018) 275:2145–9. 10.1007/s00405-018-5046-9
    1. Simon C, Dietz A, Leemans CR. Quality assurance in head and neck cancer surgery: where are we, and where are we going? Curr Opin Otolaryngol Head Neck Surg. (2019) 27:151–6. 10.1097/MOO.0000000000000519
    1. Collins R, Flynn A, Melville A, Richardson R, Eastwood A. Effective health care: management of head and neck Cancers. Qual Saf Health Care. (2005) 14:144–8. 10.1136/qshc.2005.013961
    1. National Institute for Clinical Excellence (NICE) Guidance on Cancer Services: Improving Outcomes in Head and Neck Cancers: The Manual. London: NICE; (2004).
    1. Therasse P, De Mulder PH. Quality assurance in medical oncology within the EORTC. European Organisation for Research and Treatment of Cancer. Eur J Cancer. (2002) 38:S152–4. 10.1016/S0959-8049(01)00437-3
    1. Digue L, Pedeboscq S. Quality assurance in head and neck medical oncology. Bull Cancer. (2014) 101:486–95. 10.1684/bdc.2014.1968
    1. Jensen AR, Nellemann HM, Overgaard J. Tumor progression in waiting time for radiotherapy in head and neck cancer. Radiother Oncol. (2007) 84:5–10. 10.1016/j.radonc.2007.04.001
    1. Grégoire V, Lefebvre JL, Licitra L, Felip E, EHNS-ESMO-ESTRO Guidelines Working Group . Squamous cell carcinoma of the head and neck: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2010) 21:vi184–6. 10.1093/annonc/mdq185
    1. De Felice F, Tombolini V, de Vincentiis M, Magliulo G, Greco A, Valentini V, et al. . Multidisciplinary team in head and neck cancer: a management model. Med Oncol. (2018) 36:2. 10.1007/s12032-018-1227-z
    1. Badran KW, Heineman TE, Kuan EC, St. John MA. Is multidisciplinary team care for head and neck cancer worth it? Laryngoscope. (2018) 128:1257–8. 10.1002/lary.26919
    1. Bergamini C, Locati L, Bossi P, Granata R, Alfieri S, Resteghini C, et al. . Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer? Oral Oncol. (2016) 54:54–7. 10.1016/j.oraloncology.2016.01.001
    1. Brunner M, Gore SM, Read RL, Alexander A, Mehta A, Elliot M, et al. . Head and neck multidisciplinary team meetings: effect on patient management. Head Neck. (2015) 37:1046–50. 10.1002/hed.23709
    1. Cionini L, Gardani G, Gabriele P, Magri S, Morosini PL, Rosi A, et al. . Quality indicators in radiotherapy. Radiother Oncol. (2007) 82:191–200. 10.1016/j.radonc.2006.12.009
    1. Lee AW, Ng WT, Pan JJ, Poh SS, Ahn YC, AlHussain H, et al. . International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. Radiother Oncol. (2018) 126:25–36. 10.1016/j.radonc.2017.10.032
    1. Grégoire V, Evans M, Le QT, Bourhis J, Budach V, Chen A, et al. . Delineation of the primary tumour Clinical Target Volumes (CTV-P) in laryngeal, hypopharyngeal, oropharyngeal and oral cavity squamous cell carcinoma: AIRO, CACA, DAHANCA, EORTC, GEORCC, GORTEC, HKNPCSG, HNCIG, IAG-KHT, LPRHHT, NCIC CTG, NCRI, NRG Oncology, PHNS, SBRT, SOMERA, SRO, SSHNO, TROG consensus guidelines. Radiother Oncol. (2018) 126:3–24. 10.1016/j.radonc.2017.10.016
    1. Grégoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, et al. . Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol. (2014) 110:172–81. 10.1016/j.radonc.2013.10.010
    1. Szturz P, Wouters K, Kiyota N, Tahara M, Prabhash K, Noronha V, et al. . Low-dose vs. high-dose cisplatin: lessons learned from 59 chemoradiotherapy trials in head and neck cancer. Front Oncol. (2019) 9:86. 10.3389/fonc.2019.00086
    1. Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, et al. . Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol. (2014) 32:3858–66. 10.1200/JCO.2014.55.3925
    1. O'Sullivan B, Huang SH, Siu LL, Waldron J, Zhao H, Perez-Ordonez B, et al. . Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol. (2013) 31:543–50. 10.1200/JCO.2012.44.0164
    1. Strojan P, Vermorken JB, Beitler JJ, Saba NF, Haigentz M, Jr., Bossi P, et al. . Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: a systematic review. Head Neck. (2016) 38(Suppl 1):E2151–8. 10.1002/hed.24026
    1. Ouwens MM, Marres HA, Hermens RR, Hulscher MM, van den Hoogen FJ, Grol RP, et al. . Quality of integrated care for patients with head and neck cancer: development and measurement of clinical indicators. Head Neck. (2007) 29:378–86. 10.1002/hed.20532
    1. Ouwens MM, Hermens RR, Hulscher MM, Merkx MA, van den Hoogen FJ, Grol RP, et al. . Impact of an integrated care program for patients with head and neck cancer on the quality of care. Head Neck. (2009) 31:902–10. 10.1002/hed.21041
    1. Gatta G, Botta L, Sánchez MJ, Anderson LA, Pierannunzio D, Licitra L, et al. . Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. Eur. J. Cancer. (2015) 51:2130–43. 10.1016/j.ejca.2015.07.043
    1. Mackillop WJ. Killing time: the consequences of delays in radiotherapy. Radiother Oncol. (2007) 84:1–4. 10.1016/j.radonc.2007.05.006
    1. Grau C, Defourny N, Malicki J, Dunscombe P, Borras JM, Coffey M, et al. . Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey. Radiother Oncol. (2014) 112:155–64. 10.1016/j.radonc.2014.08.029
    1. Rudat V, Wannenmacher M. Role of multimodal treatment in oropharynx, larynx, and hypopharynx cancer. Semin Surg Oncol. (2001) 20:66–74. 10.1002/ssu.1018
    1. Hamaker ME, Smorenburgc CH, Bund RJ, de Kuyper GT, van Munster BC, de Rooij SE, et al. Age-related differences in guideline adherence for head and neck cancer. J Geriatric Oncol. (2012) 3:329–36. 10.1016/j.jgo.2012.07.004
    1. Lewis CM, Nurgalieva Z, Sturgis EM, Lai SY, Weber RS. Improving patient outcomes through multidisciplinary treatment planning conference. Head Neck. (2016) 38:E1820–5. 10.1002/hed.24325
    1. Lewis CM, Hessel AC, Roberts DB, Guo YZ, Holsinger FC, Ginsberg LE, et al. . Prereferral head and neck cancer treatment: compliance with National Comprehensive Cancer Network Treatment Guidelines. Arch Otolaryngol Head Neck Surg. (2010) 136:1205–11. 10.1001/archoto.2010.206
    1. Alfieri S, Orlandi E, Bossi P. The case volume issue in head and neck oncology. Curr Treat Options Oncol. (2017) 2718:65 10.1007/s11864-017-0507-8
    1. Nieman CL, Stewart CM, Eisele DW, Pronovost PJ, Gourin CG. Frailty, hospital volume, and failure to rescue after head and neck cancer surgery. Laryngoscope. (2018) 128:1365–70. 10.1002/lary.26952
    1. Eskander A, Merdad M, Irish JC, Hall SF, Groome PA, Freeman JL, et al. . Volume-outcome associations in head and neck cancer treatment: a systematic review and meta-analysis. Head Neck. (2014) 36:1820–34. 10.1002/hed.23498
    1. Orlandi E, Alfieri S, Simon C, Trama A, Licitra L, RARECAREnet Working Group . Treatment challenges in and outside a network setting: head and neck cancers. Eur J Surg Oncol. (2019) 45:40–5. 10.1016/j.ejso.2018.02.007
    1. Gatta G, Capocaccia R, Botta L, Mallone S, De Angelis R, Ardanaz E, et al. . Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet a population-based study. Lancet Oncol. (2017) 18:1022–39. 10.1016/S1470-2045(17)30445-X

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner